Clear Cell Renal Cell Carcinoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 31 expanded access programs, clinical trials, and compassionate use pathways listed for Clear Cell Renal Cell Carcinoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with clear cell renal cell carcinoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 12 programs are currently active or recruiting, with the remaining 19 in other lifecycle stages. Sponsors actively running programs in this area include National Cancer Institute (NCI), M.D. Anderson Cancer Center, NiKang Therapeutics, Inc., Adicet Therapeutics, Ajjai Alva, MD, and others.
By recruiting status
Snapshot of where every Clear Cell Renal Cell Carcinoma program currently sits in its lifecycle.
- Active / Recruiting12
- Inactive19
Top sponsors
Organisations running the most Clear Cell Renal Cell Carcinoma programs in the directory.
- National Cancer Institute (NCI)4 programs
- M.D. Anderson Cancer Center3 programs
- NiKang Therapeutics, Inc.2 programs
- Adicet Therapeutics1 program
- Ajjai Alva, MD1 program
- Alliance for Clinical Trials in Oncology1 program
- Bilal G. Rahim1 program
- Bolt Biotherapeutics, Inc.1 program
- Bristol-Myers Squibb1 program
- City of Hope Medical Center1 program
Clear Cell Renal Cell Carcinoma programs (31)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Entinostat and Aldesleukin for Treating Advanced Kidney Cancer — National Cancer Institute (NCI)
- Study on Immunotherapy with Nivolumab and Ipilimumab, Followed by Nivolumab or Nivolumab with Cabozantinib for Advanced Kidney Cancer — National Cancer Institute (NCI)
- Study on Cabozantinib Before Surgery for Locally Advanced Kidney Cancer — Emory University
- Study on Pazopanib Hydrochloride and Bevacizumab for Treating Metastatic Kidney Cancer — Roswell Park Cancer Institute
- Study on Pazopanib Hydrochloride for Patients with Metastatic Kidney Cancer with No Disease Signs After Surgery — National Cancer Institute (NCI)
- Study on Combination Treatment with 177Lu Girentuximab, Cabozantinib, and Nivolumab for Patients with Advanced Clear Cell Kidney Cancer — M.D. Anderson Cancer Center
- Phase II Study of Belzutifan or Pembrolizumab Alone Versus Combined as Pre-Surgery Treatment for Clear Cell Kidney Cancer (BLAZE) — M.D. Anderson Cancer Center
- Study on Axitinib's Role in Improving Kidney Surgery Outcomes for Renal Cancer — University of California, San Diego
- Study on Durvalumab and Guadecitabine for Advanced Kidney Cancer — Ajjai Alva, MD
- Study on PF-08634404 Alone and with Other Cancer Treatments for Advanced Kidney Cancer — Pfizer
- Study on Adding Tivozanib to Immunotherapy After Surgery for Kidney Cancer — Alliance for Clinical Trials in Oncology
- Study on XL092 with Immunotherapy for Patients with Clear Cell Kidney Cancer After Previous Treatment — Karie Runcie
- Expanded Access Program for 89Zr-DFO-girentuximab to Detect Kidney Cancer — Telix Pharmaceuticals (Innovations) Pty Limited
- Study on Beta-only IL-2 Immunotherapy for Advanced Solid Tumors — Medicenna Therapeutics, Inc.
- Study on ADI-270 for Treating Advanced Clear Cell Kidney Cancer — Adicet Therapeutics
- Study on the Safety and Effectiveness of CTX131 for Adults with Returning or Hard-to-Treat Solid Tumors — CRISPR Therapeutics AG
- A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma — NiKang Therapeutics, Inc.
- Study Comparing Subcutaneous and Intravenous Nivolumab in Patients with Advanced or Metastatic Clear Cell Kidney Cancer — Bristol-Myers Squibb
- Study on Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for Treating Kidney Cancer After Surgery — City of Hope Medical Center
- Study Comparing a New PET/CT Scan with Standard CT for Detecting Recurrent Kidney Cancer After Surgery — Jonsson Comprehensive Cancer Center
- Study on Belzutifan for Monitoring or Treating Slow-Growing Metastatic Kidney Cancer — M.D. Anderson Cancer Center
- Study on Cemiplimab or Cemiplimab and Fianlimab After Radiation Therapy for Clear Cell Kidney Cancer — University of Oklahoma
- Study on Ceralasertib Alone and Combined with Olaparib or Durvalumab for Patients with Solid Tumors — Rahul Aggarwal
- Study on Pembrolizumab With or Without Axitinib for Treating Advanced Kidney Cancer in Patients Undergoing Surgery — University of California, San Francisco
- Phase 2 Study of NKT2152 with Palbociclib and Sasanlimab for Advanced Clear Cell Kidney Cancer — NiKang Therapeutics, Inc.
- Study on Seleno-L Methionine, Axitinib, and Pembrolizumab for Advanced Kidney Cancer — Bilal G. Rahim
- Study on Adaptive Immunotherapy with VEGFR-TKI for Patients with Advanced Kidney Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Study of BDC-3042 Alone and with Cemiplimab in Patients with Advanced Cancers — Bolt Biotherapeutics, Inc.
- Study of Nivolumab Combined with 177Lu-girentuximab for Kidney Cancer — Memorial Sloan Kettering Cancer Center
- Study on Adding Radium-223 to Usual Treatment for Advanced Kidney Cancer Spread to the Bone — National Cancer Institute (NCI)
- Study on Zanzalintinib for Advanced Kidney Cancer with Bone Spread — Kelly Fitzgerald, MD
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Clear Cell Renal Cell Carcinoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.